|Bid||80.25 x 100|
|Ask||80.26 x 200|
|Day's Range||79.95 - 80.45|
|52 Week Range||76.41 - 89.72|
|PE Ratio (TTM)||39.16|
|Earnings Date||May 24, 2018|
|Forward Dividend & Yield||1.84 (2.31%)|
|1y Target Est||90.84|
April 23, 2018 - Medtronic plc (MDT) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the IN.PACT(TM) Admiral(TM) Drug-Coated Balloon (DCB) to treat long superficial femoral artery (SFA) lesions up to 360mm in patients with peripheral artery disease (PAD). Approval was based on clinical data from the complex lesion imaging cohorts of the IN.PACT Global Study, including long lesion, in-stent restenosis, and chronic total occlusion (CTO) groups with lesion lengths 180mm.
WESTMINSTER, Colo., April 23, 2018-- ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today ...
Edwards Lifesciences, Medtronic, Boston Scientific and Abbott Laboratories are duking it out for a share of the fast-growing heart-valve replacement market.
IntriCon Corporation (NASDAQ: IIN ), a medical technology company and major supplier to Medtronic PLC (NYSE: MDT )'s diabetes division, is "one of the more interesting and undiscovered small-cap ...
Product Line Offers Unique, Resorbable Option for Patients with Hypervascular Tumors DUBLIN - April 17, 2018 - Medtronic plc (NYSE: MDT) today announced its U.S. launch of OptiSphere(TM) embolization spheres, ...
When a stock jumps over 85% higher in a month and around 30 percent in just the last week, value investors would typically lose interest in the stock. Value investors would likely only consider buying TNDM stock on a pullback. Regardless of one’s investing style, the first step is looking into why Tandem Diabetes stock is soaring since February and then picking up steam in April.
On April 6, 2018, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings ratio) of 20.1x, while its PE was 57.6x. A lower forward estimate compared to the current PE represents analysts’ expectations that a company will generate higher earnings over the next 12 months.
The dividend will be payable on May 15, 2018, to shareholders of record on April 13, 2018. Abbott Laboratories is part of the S&P 500 Dividend Aristocrats, which are the companies that have paid out consistently increasing dividends to shareholders for at least 25 consecutive years. As of April 6, 2018, ABT stock has a dividend yield of 1.9%.
On April 5, 2018, Abbott Laboratories (ABT) ended the trading day at $59.86 per share. The stock registered a rise of ~0.67% in its stock price compared to its previous day’s close. For more details, read Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results.
Abbott Laboratories (ABT) showed an impressive performance in 2017 despite a challenging macroeconomic environment and big-ticket acquisitions. The company reported strong 2017 results on January 24, 2018, and it has secured a number of product approvals and reimbursement approvals since then, strengthening its market position.
The Maple Grove-based company, which spun out of Medtronic in 2007, plans to put the proceeds toward sales and marketing, product development and working capital.
Data on Implant Approach, Blood Pressure Management, Length of Stay, and Quality of Life to be Featured During Congress. DUBLIN - April 9, 2018 - Medtronic plc (NYSE: MDT) today announced a preview of ...
On March 19, 2018, Abbott Laboratories (ABT) announced that it had received reimbursement approval for its MitraClip device in Japan. MitraClip is a minimally invasive procedure for patients suffering from MR (mitral regurgitation) who are at high risk of open surgery.
Pivotal Trial Now Underway to Study Effect of Investigational Procedure in Patients with High Blood Pressure DUBLIN - April 9, 2018 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration ...
Medtronic's (MDT) latest restructuring Enterprise Excellence plan intends to achieve $3 billion of annual growth run rate savings by the end of fiscal 2022
On March 23, 2018, Edwards Lifesciences (EW) announced that it won its dispute with Boston Scientific (BSX) over US Patent 8992608. The USPTO (US Patent and Trademark Office) decided in favor of Edwards in an inter partes review filed by Boston Scientific against Edwards for its TAVR (transcatheter aortic valve replacement) technology, finding all the related claims against Edwards to be invalid.